A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions
Type 2 Diabetes MellitusChronic Kidney Diseases
Interventions
DRUG

Cotadutide 100 micrograms

Cotadutide 100 micrograms administered subcutaneously

DRUG

Cotadutide 300 micrograms

Cotadutide 300 micrograms administered subcutaneously

DRUG

Cotadutide 600 micrograms

Cotadutide 600 micrograms administered subcutaneously

DRUG

Semaglutide

Semaglutide 1.0 miligrams administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously

Trial Locations (83)

1010

Research Site, Grafton

2025

Research Site, Auckland

2291

Research Site, Merewether

2500

Research Site, Wollongong

3004

Research Site, Melbourne

3065

Research Site, Fitzroy

3084

Research Site, Heidelberg

3110

Research Site, Tauranga

3128

Research Site, Box Hill

4102

Research Site, Woolloongabba

4130

Research Site, Havelock North

4310

Research Site, New Plymouth

5046

Research Site, Oaklands Park

5112

Research Site, Elizabeth Vale

6021

Research Site, Wellington

8011

Research Site, Christchurch

10409

Research Site, Berlin

10437

Research Site, Berlin

10789

Research Site, Berlin

14004

Research Site, Córdoba

15006

Research Site, A Coruña

20064

Research Site, Lublin

25198

Research Site, Lleida

28006

Research Site, Madrid

28222

Research Site, Majadahonda

28223

Research Site, Pozuelo de Alarcón

29010

Research Site, Málaga

34121

Research Site, Kassel

39120

Research Site, Magdeburg

40210

Research Site, Düsseldorf

41003

Research Site, Seville

41009

Research Site, Seville

44137

Research Site, Dortmund

45359

Research Site, Essen

46009

Research Site, Valencia

48145

Research Site, Münster

48153

Research Site, Münster

55116

Research Site, Mainz

66386

Research Site, Sankt Ingbert

67059

Research Site, Ludwigshafen

81241

Research Site, München

V5Y 3W2

Research Site, Vancouver

L4N 7L3

Research Site, Barrie

L6S 0C6

Research Site, Brampton

L4K 4M2

Research Site, Concord

M9R 4E1

Research Site, Etobicoke

L6M 1M1

Research Site, Oakville

L1G 2B9

Research Site, Oshawa

K2J 0V2

Research Site, Ottawa

M4G 3E8

Research Site, Toronto

M5G 2C4

Research Site, Toronto

N2T 0C1

Research Site, Waterloo

H7T 2P5

Research Site, Laval

H4A 2C6

Research Site, Montreal

01587

Research Site, Riesa

116-0012

Research Site, Arakawa-ku

066-0032

Research Site, Chitose-shi

251-0041

Research Site, Fujisawa-shi

247-8533

Research Site, Kamakura-shi

080-0848

Research Site, Obihiro-shi

060-0062

Research Site, Sapporo

160-0022

Research Site, Shinjyuku-ku

?0620

Research Site, Auckland

15-435

Research Site, Bialystok

05-825

Research Site, Grodzisk Mazowiecki

40-081

Research Site, Katowice

30-033

Research Site, Krakow

31-261

Research Site, Krakow

31-530

Research Site, Krakow

61-655

Research Site, Poznan

96-100

Research Site, Skierniewice

00-660

Research Site, Warsaw

01-518

Research Site, Warsaw

02-507

Research Site, Warsaw

33-122

Research Site, Wierzchosławice

08036

Research Site, Barcelona

08907

Research Site, L'Hospitalet de Llobregat

07198

Research Site, Palma

07010

Research Site, Palma de Mallorca

01009

Research Site, Vitoria-Gasteiz

DD1 9SY

Research Site, Dundee

L9 7AL

Research Site, Liverpool

SE5 9RS

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY